Miniatura

Fitxers

Determinants of HBsAg loss in caucasian population.pdf (724.15 KB)

Embargament

Document embargat fins el 2026-10-13

Tipus de document

Article

Data de publicació

2025-10-13

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/227673

Determinants of HBsAg Loss After Nucleos(t)ide Discontinuation in a Prospective Cohort of HBeAg-Negative Caucasian Patients

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1111/liv.70371

Resum

Introduction: Nucleos(t)ide analogues (NAs) discontinuation in HBeAg-negative chronic hepatitis B (CHB) aims at increasing functional cure rates. However, clinical outcomes and predictive factors for HBsAg loss or re-treatment are affected by the heterogeneity of studies. We aimed to analyse baseline factors associated with outcomes after NAs discontinuation in a cohort with homogeneous re-treatment criteria. Methods: Prospective multicenter study of 149 HBeAg-negative CHB with complete viral suppression and absence of cirrhosis recruited from 2016 to 2021. Re-treatment criteria after NAs discontinuation were homogeneous based on liver tests and HBV-DNA levels. Results: In this predominantly Caucasian cohort, 71% received tenofovir with a median treatment duration of 10 (7-13) years. Forty patients (27%) achieved HBsAg loss after 44 (28-54) months. Lower qHBsAg at end of treatment (EOT) and longer treatment duration were independent predictors of HBsAg loss. Combining qHBsAg at EOT (1000 IU/mL) and month 3 after NA interruption (100 IU/mL) stratified patients into high (> 70%) or low (< 10%) likelihood of HBsAg loss. On the other hand, 43 (29%) patients were retreated; HBV-DNA < 100 IU/mL at month 3 was significantly associated with remaining off-therapy. Overall, safety was favourable, with mild or transient ALT flares occurring in 64 patients (43%). However, one patient (0.6%) developed a severe hepatitis and required liver transplantation. Conclusions: NA withdrawal results in functional cure rates exceeding 25%, particularly in patients with long-term antiviral treatment and low qHBsAg levels. Combining qHBsAg levels at EOT and at 3 months accurately stratifies patients according to the probability of HBsAg loss. Close monitoring to detect the need for treatment re-introduction is mandatory.

Matèries

Matèries (anglès)

Citació

Col·leccions

Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

POCURULL APARICIO, Anna, BROQUETAS, Teresa, HOYAS, Elena, RODRIGUEZ, Manuel, MIQUEL, Mireia, RODRIGUEZ, Mercedes, ROIG, Clara amiama, HERMS RUBIÓ, Queralt, RODRÍGUEZ TAJES, Sergio, GARCIA-SAMANIEGO, Javier, SUAREZ, Emilio, BUTI, Maria, FORNS BERNHARDT, Xavier, CARRION, Jose a, LENS GARCÍA, Sabela. Determinants of HBsAg Loss After Nucleos(t)ide Discontinuation in a Prospective Cohort of HBeAg-Negative Caucasian Patients. _Liver International_. 2025. Vol.  45, núm. 11, pàgs. e70371. [consulta: 28 de febrer de 2026]. ISSN: Pocurull, Anna; Broquetas, Teresa; Hoyas, Elena; Rodriguez, Manuel; Miquel, Mireia; Rodriguez, Mercedes; Roig, Clara Amiama; Herms, Queralt; Rodriguez (2025). Determinants of HBsAg Loss After Nucleos(t)ide Discontinuation in a Prospective Cohort of HBeAg-Negative Caucasian Patients. Liver International, 45(11), e70371-. DOI: 10.1111/liv.70371. [Disponible a: https://hdl.handle.net/2445/227673]

Exportar metadades

JSON - METS

Compartir registre